Summary

Eligibility
for people ages 18 years and up (full criteria)
Healthy Volunteers
healthy people welcome
Location
at UCSF
Dates
study started
completion around
Principal Investigator
by Ellen Herbst, MD (ucsf)
Headshot of Ellen Herbst
Ellen Herbst

Description

Summary

Tobacco and cannabis co-use is a common and growing public health problem, especially in states that have legalized cannabis. There are no pharmacologic treatments for co-occurring tobacco and cannabis use. Co-use may make quitting either substance more difficult, given the synergistic effects of cannabis and nicotine on neurobiological systems that mediate reward and shared cues reinforcing co-use. N-acetylcysteine (NAC), an FDA-approved medication and over-the-counter supplement, has shown promise in animal studies and randomized controlled trials (RCTs) in reducing tobacco and cannabis craving and use.

Official Title

N-Acetylcysteine for Smoking Cessation in Tobacco and Cannabis Co-Use: a Randomized Controlled Trial

Details

Keywords

Cannabis Use, Tobacco Use Disorder, Drug Use Disorder, Tobacco, Cannabis, N-acetylcysteine, NAC, Marijuana Abuse, Substance-Related Disorders, Acetylcysteine, N-monoacetylcystine, N-Acetyl cysteine, Cognitive behavioral therapy (CBT), N-acetyl cysteine (NAC) & cognitive behavioral therapy

Eligibility

Location

  • San Francisco Veterans Affairs Medical Center
    San Francisco California 94121 United States

Lead Scientist at University of California Health

  • Ellen Herbst, MD (ucsf)
    Professor, Psychiatry, School of Medicine. Authored (or co-authored) 34 research publications

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Ellen Herbst
Links
Provides Link to NAC Study (in development)
ID
NCT04627922
Phase
Phase 4 research study
Study Type
Interventional
Participants
About 59 people participating
Last Updated